nach oben

The European Journal of Health Economics

Erschienen in:

01.03.2006 | Original Papers

Case-control analysis of the financial cost of medication errors in hospitalized patients

verfasst von: Jaime Pinilla, Carles Murillo, Genís Carrasco, Carlos Humet

Erschienen in: The European Journal of Health Economics | Ausgabe 1/2006

Einloggen, um Zugang zu erhalten

Abstract

The cost of medication errors (MEs), and by extension their impact on the running of hospitals, is generally unknown to hospital managers. This study estimated the financial costs involved in the additional use of hospital resources as a result of MEs. For this we used a database covering 20,014 hospital admissions, with clinical and personal information about each patient, the costs related to his/her stay, and physicians’ prescriptions. Analyses were carried out using cases and control techniques to calculate the additional cost of MEs. During the study period, 2001, the analysis indicated that the MEs analyzed caused an additional 303 days of hospital stay, with an overall annual cost of nearly €76,000. Our study confirms that MEs are a costly reality. The presence of MEs doubled the cost per patient.

Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, Laffel G, Sweitzer BJ, Shea BF, Hallisey R et al. (1995) Incidence of adverse drug events and potential adverse drug events. Implications for prevention. JAMA 274:29–34CrossRefPubMed

Lesar TS, Briceland L, Stein DS (1997) Factors related to errors in medication prescribing. JAMA 277:312–317CrossRefPubMed

Classen DC, Pestotnik SL, Evans RS (1997) Adverse drugs events in hospitalised patients. Excess of length of stay, extra cost and attributable mortality. JAMA 277:301–306CrossRefPubMed

Kohn LT, Corrigan, Donaldson MS (ed) (1999) To err is human: building a safer health system. National Academy: Washington

Phillips J, Beam S, Brinker A, Holquist C, Honig P, Lee LY, Pamer C (2001) Retrospective analysis of mortalities associated with medication errors. Am J Health Syst Pharm 58:1835–1841PubMed

Blasco P, Mariño E, Aznar MT, Pol E, Alós M, Castells M, Velasco ML (2001) Desarrollo de un método observacional prospectivo de estudio de Errores de Medicación para su aplicación en hospitales. Farm Hosp 25:253–273

Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, Leape LL (1997) The costs of adverse drug events in hospitalized patients. JAMA 277:307–311CrossRefPubMed

Lacasa C, Polo C, Andreu C, Roure C, Martínez J, Cot R (1998) Detección de errores de medicación en hospitales. Evaluación de la calidad del proceso de prescripción, dispensación y administración de medicamentos. Rev Calid Asist 13:92–100

Leape L, Brennan T, Laird N et al. (1991) The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 324:377–384

10.

Evans RS, Classen DC, Stevens LE et al. (1993) Using a hospital information system to assess the effects of adverse drug events. Proc Annu Symp Comput Appl Med Care 17:161–165

11.

Vargas E, Terleira A, Hernando F, Perez E, Cordon C, Moreno A, Portoles A (2003) Effect of adverse drug reactions on length of stay in surgical intensive care units. Crit Care Med 31:694–698CrossRefPubMed

12.

Graf J (2003) Do you know the frequency of errors in your intensive care unit? Crit Care Med 31:1277–1278CrossRefPubMed

13.

Charlson ME, Hollenberg JP, Hou J, Cooper M, Pochapin M, Pecker M (2000) Realizing the potential of clinical judgment: a real-time strategy for predicting outcomes and costs for medical inpatients. Am J Med 109:189–195CrossRefPubMed

14.

Leape LL (2002) Reporting of adverse events. N Engl J Med 347:1633–1638CrossRefPubMed

15.

Brennan TA (2000) Reporting of errors: how much should the public know? Eff Clin Pract 3:298–299PubMed

16.

Figueiras A, Tato F, Fontainas J, Takkouche B, Gestal-Otero JJ (2001) Physicians’ attitudes towards voluntary reporting of adverse drug events. J Eval Clin Pract 7:347–354CrossRefPubMed

17.

Thompson CB, Snyder-Halpern R, Staggers N (1999) Analysis, processes, and techniques. Case study. Comp Nurs 17:203–206

18.

Leape LL, Berwick DM (2000) Safe health care: are we up to it? BMJ 320:725–726CrossRefPubMed

19.

Senst BL, Achusim LE, Genest RP, Cosentino LA, Ford CC, Little JA, Raybon SJ, Bates DW (2001) Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 58:1126–1132PubMed

20.

Otero MJ, Bajo A, Maderuelo JA, Domínguez-Gil A (1999) Evitabilidad de los acontecimientos inducidos por medicamentos detectados en un servicio de urgencias. Rev Clínica Española 199:796–804

21.

J Lazarou, BM Pomeranz, PN Corey (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200–1205CrossRefPubMed

22.

Vincent C, Neale G, Woloshynowych M (2001) Adverse events in British hospitals: preliminary retrospective record review. BMJ 322: 517–519CrossRefPubMed

23.

Senst BL, Achusim LE, Genest RP et al. (2001) Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 58:1126–1132PubMed

24.

Wu AW (2000) Medical error: the second victim. The doctor who makes the mistake needs help too. BMJ 320:726–727CrossRefPubMed

25.

Nordgren LD, Johnson T, Kirschbaum M, Peterson ML (2004) Medical errors: excess hospital costs and lengths of stay. J Healthc Qual 26:42–48PubMed

26.

Otero MJ, Domínguez-Gil A (2000) Acontecimientos adversos por medicamentos: una patología emergente. Farm Hosp 24:258–266

Titel: Case-control analysis of the financial cost of medication errors in hospitalized patients
verfasst von: Jaime Pinilla
Carles Murillo
Genís Carrasco
Carlos Humet
Publikationsdatum: 01.03.2006
Verlag: Springer-Verlag
Erschienen in: The European Journal of Health Economics / Ausgabe 1/2006
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-005-0332-z

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2006

Off-patent drugs in Italy

The Danish effect on Swedish alcohol costs

Thank you to the referees 2005

Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients

Prospective casemix-based funding, analysis and financial impact of cost outliers in all-patient refined diagnosis related groups in three Belgian general hospitals

Pharmacoeconomic modelling in schizophrenia